Phase II trial of ophthalmic fluticasone propionate (AC-155) nanocrystals in patients with acute exacerbation of blepharitis

Trial Profile

Phase II trial of ophthalmic fluticasone propionate (AC-155) nanocrystals in patients with acute exacerbation of blepharitis

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2017

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Blepharitis; Ocular inflammation; Ocular pain
  • Focus First in man; Therapeutic Use
  • Sponsors NicOx
  • Most Recent Events

    • 05 Jan 2017 Planned initiation date changed from 1 Dec 2015 to 1 Oct 2017, as reported in a NicOx media release that states the company plans to initiate this trial during the fourth quarter of 2017.
    • 20 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top